SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Seattle Genetics (SGEN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who started this subject7/30/2004 12:02:59 AM
From: mopgcw   of 161
 
WRH: SOLID FUNDAMENTALS; COMPELLING VALUATION; REITERATE BUY
2004-07-28 09:05 (New York)

We reiterate our Buy rating based on recent company developments, strong
fundamentals, and compelling valuation. Our positive thesis remains intact
given the company's industry-leading technology, multiple proprietary
clinical candidates, key partnerships, internal drug development
expertise, and numerous partnering opportunities. We expect clinical data
presentations in December 2004 and one or more partnering announcements in
H2:04 to create shareholder value in the near- to mid-term. We reiterate
our Buy rating and $16 price target, or 34x our 2009 EPS estimate of
$1.36, discounted at 30%.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News